Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Saccharomyces cerevisiae CNCM I-3856 is a probiotic yeast strain that modulates gut-brain axis signaling through tryptophan metabolism and serotonin regulation. This specific strain demonstrates clinically proven efficacy in reducing IBS symptoms across all subtypes, with particular benefits for abdominal pain and stool consistency.
Origin & History
Saccharomyces cerevisiae CNCM I-3856 is a proprietary probiotic yeast strain registered in the French National Collection of Cultures of Microorganisms, originally derived from baker's yeast. It is characterized through advanced genetic and phenotypic methods including 26S DNA sequencing and genome analysis, and is produced as either live or inactivated whole yeast cells.
Research Narrative (Provisional)
Clinical evidence includes a large RCT (n=379) showing benefits specifically in IBS-C subgroups (PMID: 27403301), and a meta-analysis of two RCTs (n=579) demonstrating 12.3% reduction in abdominal pain/discomfort (PMID: 28127207). Additional trials confirmed efficacy at 2 billion CFU twice daily for improving stool consistency across IBS subtypes (PMID: 31807856).
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Saccharomyces cerevisiae CNCM I-3856 is a probiotic yeast strain administered primarily for its bioactive and functional properties rather than macronutrient contribution. As a yeast-based organism, its nutritional composition per typical therapeutic dose (500mg or ~10 billion CFU) includes: Protein: approximately 40-50% of dry cell weight, predominantly intracellular proteins and cell wall mannoproteins (not bioavailable in intact live form); Beta-glucans: 25-35% of cell wall dry weight as (1,3)/(1,6)-beta-D-glucans, which contribute to immunomodulatory effects; Mannan-oligosaccharides (MOS): approximately 20-30% of cell wall, supporting gut microbiota modulation; B-vitamins: naturally contains thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), and folate (B9) in trace amounts per dose — insufficient to meet RDA at standard probiotic dosing; Minerals: contains intracellular selenium (as selenomethionine, strain-dependent), zinc, chromium, and iron in trace quantities; Ergosterol (provitamin D2 precursor): present in cell membrane, minimal conversion at standard dosing; Trehalose: intracellular disaccharide serving as cryoprotectant, minimal systemic contribution; Bioavailability note: As a live probiotic organism, macronutrients within intact cells are largely not bioavailable to the host; biological effects are mediated through cell wall components (beta-glucans, mannoproteins), metabolic byproducts (short-chain fatty acids, CO2), and host immune modulation rather than direct nutritional delivery. The strain is typically delivered in lyophilized capsule form at 500mg/day in clinical studies.
Reported Mechanism (Provisional)
This probiotic yeast modulates the gut-brain axis by regulating tryptophan metabolism and enhancing local serotonin production in the intestinal mucosa. It strengthens intestinal barrier function through increased tight junction protein expression and reduces visceral hypersensitivity by modulating afferent nerve signaling. The strain also produces bioactive metabolites that influence enteric nervous system function and normalize gut motility patterns.
Clinical Narrative (Provisional)
A meta-analysis of 2 randomized controlled trials (n=579) demonstrated a 12.3% reduction in abdominal pain and bloating in IBS-C patients. Additional RCT evidence shows significant improvements in stool consistency across IBS-D (p<0.001), IBS-C, and IBS-M subtypes. The clinical evidence is moderate quality, with studies focusing primarily on functional gastrointestinal disorders. Most trials used dosages of 5-10 billion CFU daily for 4-8 week intervention periods.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.